News
NERV
4.815
-2.13%
-0.105
Weekly Report: what happened at NERV last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at NERV last week (0622-0626)?
Weekly Report · 06/29 09:56
Weekly Report: what happened at NERV last week (0615-0619)?
Weekly Report · 06/22 10:02
Weekly Report: what happened at NERV last week (0608-0612)?
Weekly Report · 06/15 10:03
Weekly Report: what happened at NERV last week (0601-0605)?
Weekly Report · 06/08 10:00
Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia
PUBT · 06/05 11:28
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
TipRanks · 06/04 21:12
Minerva Neurosciences shareholders approve charter amendments at annual meeting
PUBT · 06/04 20:08
MINERVA NEUROSCIENCES - TOPLINE DATA FROM 12-WEEK PHASE A EXPECTED IN SECOND HALF OF 2027
Reuters · 06/01 20:08
Minerva Neurosciences forms scientific advisory board for roluperidone program
PUBT · 06/01 20:05
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Barchart · 06/01 15:05
Weekly Report: what happened at NERV last week (0525-0529)?
Weekly Report · 06/01 10:03
Minerva Neurosciences Launches ATM Offering to Fund Trial
TipRanks · 05/27 21:25
CORRECTION: Minerva Neurosciences Establishes $75M At-The-Market Stock Offering Program With Leerink Partners
Benzinga · 05/27 20:57
Minerva Neurosciences To Offer Up To $75M In Common Stock Offering
Benzinga · 05/27 20:51
Minerva Neurosciences enters equity distribution deal for up to $75 million ATM offering
PUBT · 05/27 20:22
MINERVA NEUROSCIENCES - TO OFFER AND SELL UP TO $75 MLN IN COMMON STOCK THROUGH LEERINK PARTNERS - SEC FILING
Reuters · 05/27 20:15
Weekly Report: what happened at NERV last week (0518-0522)?
Weekly Report · 05/25 10:06
Minerva Neurosciences publishes corporate presentation on roluperidone for schizophrenia negative symptoms
PUBT · 05/19 17:13
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Barchart · 05/18 15:05
More
Webull provides a variety of real-time NERV stock news. You can receive the latest news about Minerva Neurosci through multiple platforms. This information may help you make smarter investment decisions.
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.